Skip to content
Screener

Baxter International BAX Pharmaceuticals — Depreciation

Other segment segments

Medical Products & Therapies
$51M+4.1%
Healthcare Systems & Technologies
$24M-11.1%

Similar metrics at other companies

Sunbelt Rentals Holdings logo
SUNBSpecialty — Depreciation
$141M+6.0%
Sunbelt Rentals Holdings logo
SUNBU.K. — Depreciation
$43M+2.4%
Cato Corporation logo
CATOCredit — Depreciation
$0
Cato Corporation logo
CATORetail — Depreciation
$2.24M-12.8%
CPH
CPHCDevelopment — Depreciation
$0
Crown Holdings logo
CCKOther — Depreciation
$7M0.0%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$14.13B+22.3%
Enterprise value$12.33B+22.1%
P/S1.3×+0.2×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028962
(in millions)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Depreciation Expense1
Medical Products & Therapies$51$49
Healthcare Systems & Technologies2427
Pharmaceuticals1616
Total depreciation expense$91$92

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's pharmaceuticals — depreciation?
Baxter International (BAX) reported pharmaceuticals — depreciation of $16M in Q1 2026.
How has Baxter International's pharmaceuticals — depreciation changed year-over-year?
Baxter International's pharmaceuticals — depreciation decreased by 0.0% year-over-year, from $16M to $16M.
What is the long-term trend for Baxter International's pharmaceuticals — depreciation?
Over 4 years (2021 to 2025), Baxter International's pharmaceuticals — depreciation has grown at a -2.2% compound annual growth rate (CAGR), from $71M to $65M.
What does pharmaceuticals — depreciation mean?
Represents the systematic allocation of the cost of tangible assets, such as manufacturing equipment and facilities, over their useful lives within the Pharmaceuticals segment. It is a non-cash expense that reflects the wear and tear of capital assets.

Ask your AI about Baxter International's pharmaceuticals — depreciation.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude